The purpose of this study is to evaluate infection detection and treatment initiation rates for syphilis and HIV before and after integration of the Chembio DPP® HIV-Syphilis rapid POC test into an ongoing Emergency Department (ED) testing program and to determine whether dual rapid testing improves early initiation of HIV therapy in pregnant patients with newly identified HIV infection.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
1,400
Participants will undergo dual rapid HIV/syphilis testing by fingerstick using the Chembio DPP® HIV-Syphilis System.
Laboratory-based HIV and syphilis testing
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Number of participants that tested for HIV
Time frame: Baseline
Number of participants that tested for syphilis
Time frame: Baseline
Number of participants that tested positive for syphilis and who receive same-visit treatment initiation with Benzathine Penicillin G according to the Centers for Disease Control and Prevention (CDC) 2021 Guidelines.
Time frame: about 15 minutes after baseline
Number of participants that tested positive for HIV who start antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide)
Time frame: about 15 minutes after baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.